PE20000953A1 - Composiciones farmaceuticas que contienen un inhibidor de lipasas gastrointestinales - Google Patents
Composiciones farmaceuticas que contienen un inhibidor de lipasas gastrointestinalesInfo
- Publication number
- PE20000953A1 PE20000953A1 PE1999000820A PE00082099A PE20000953A1 PE 20000953 A1 PE20000953 A1 PE 20000953A1 PE 1999000820 A PE1999000820 A PE 1999000820A PE 00082099 A PE00082099 A PE 00082099A PE 20000953 A1 PE20000953 A1 PE 20000953A1
- Authority
- PE
- Peru
- Prior art keywords
- lipase inhibitor
- orlistat
- gastrointestinal lipase
- gum
- absorbable
- Prior art date
Links
- 229940086609 Lipase inhibitor Drugs 0.000 title abstract 4
- 230000002496 gastric effect Effects 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 abstract 3
- 229960001243 orlistat Drugs 0.000 abstract 3
- 239000003995 emulsifying agent Substances 0.000 abstract 2
- 235000013305 food Nutrition 0.000 abstract 2
- 239000003921 oil Substances 0.000 abstract 2
- 239000002562 thickening agent Substances 0.000 abstract 2
- 229920000569 Gum karaya Polymers 0.000 abstract 1
- 244000134552 Plantago ovata Species 0.000 abstract 1
- 235000003421 Plantago ovata Nutrition 0.000 abstract 1
- 241000934878 Sterculia Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000007910 chewable tablet Substances 0.000 abstract 1
- 229940068682 chewable tablet Drugs 0.000 abstract 1
- 230000037213 diet Effects 0.000 abstract 1
- 235000005911 diet Nutrition 0.000 abstract 1
- 235000019621 digestibility Nutrition 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 239000000231 karaya gum Substances 0.000 abstract 1
- 229940039371 karaya gum Drugs 0.000 abstract 1
- 235000010494 karaya gum Nutrition 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
- 229920000728 polyester Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Jellies, Jams, And Syrups (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA ORAL TAL COMO UN COMPRIMIDO MASTICABLE QUE COMPRENDE: a)UN INHIBIDOR DE LIPASAS GASTROINTESTINALES TAL COMO ORLISTAT, UTILIZANDOSE DE 50mg A 150 mg; b)UNO O MAS ADITIVOS COMO: i)ESPESANTES TALES COMO GOMA DE XANTANO, GOMA KARAYA, SEMILLA DE PSILIO, CASCARA DE ISPAGULA, SEMILLAS DE PLANTAGO OVATA, METILCELULOSA; ii)UN EMULSIFICANTE TAL COMO POLIESTER DE SACAROSA; CARACTERIZADOS POR SER DE BAJA DIGESTIBILIDAD, POCA FERMENTABILIDAD, HIDROFILOS, HIDROCOLOIDES DE GRADO ALIMENTARIO. LA PROPORCION ES DE UNA PARTE EN PESO DE INHIBIDOR DE LIPASAS Y DE 1-300 PARTES EN PESO DE ESPESANTES O EMULSIFICANTES, DE PREFERENCIA DE 3 A 30 PARTES DE GOMA KARAYA O GOMA XANTANO POR UNA PARTE DE ORLISTAT. EL ORLISTAT REDUCE LA ABSORCION DE GRASAS DE LA DIETA Y LA COMPOSICION PUEDE SER UTIL PARA LA PREVENCION DEL SINDROME DE LA PERDIDA ANAL DE ACEITE QUE SE PRODUCE POR LA ADMINISTRACION DE UN INHIBIDOR DE LIPASA GASTROINTESTINAL O POR LA INGESTION DE ALIMENTOS CONTENIENDO GRASAS O ACEITES POCO ABSORBIBLES O NO ABSORBIBLES
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98115311 | 1998-08-14 | ||
| EP99109516 | 1999-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000953A1 true PE20000953A1 (es) | 2000-09-26 |
Family
ID=26149537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000820A PE20000953A1 (es) | 1998-08-14 | 1999-08-12 | Composiciones farmaceuticas que contienen un inhibidor de lipasas gastrointestinales |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6358522B1 (es) |
| EP (1) | EP1105122B1 (es) |
| JP (1) | JP3774118B2 (es) |
| KR (1) | KR20010079635A (es) |
| CN (1) | CN1170534C (es) |
| AR (1) | AR035001A1 (es) |
| AT (1) | ATE293970T1 (es) |
| AU (1) | AU761351B2 (es) |
| BR (1) | BR9912980B1 (es) |
| CA (1) | CA2340056C (es) |
| CO (1) | CO5130009A1 (es) |
| DE (1) | DE69924999T2 (es) |
| DK (1) | DK1105122T3 (es) |
| ES (1) | ES2242413T3 (es) |
| MA (1) | MA26671A1 (es) |
| PE (1) | PE20000953A1 (es) |
| PT (1) | PT1105122E (es) |
| TR (1) | TR200100471T2 (es) |
| WO (1) | WO2000009122A1 (es) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6264937B1 (en) * | 1998-01-09 | 2001-07-24 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
| US6299868B1 (en) | 1999-07-14 | 2001-10-09 | Geltex Pharmaceuticals, Inc. | Fat-binding polymers |
| US7048917B1 (en) | 1998-01-09 | 2006-05-23 | Genzyme Corporation | Fat-binding polymers |
| US6607749B1 (en) | 1998-09-08 | 2003-08-19 | Smithkline Beecham Corporation | Lipstatin derivative-soluble fiber tablets |
| AR025587A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones en dispersion que contienen inhibidores de lipasa |
| AR025609A1 (es) | 1999-09-13 | 2002-12-04 | Hoffmann La Roche | Formulaciones lipidas solidas |
| EP1132389A1 (en) | 2000-03-06 | 2001-09-12 | Vernalis Research Limited | New aza-indolyl derivatives for the treatment of obesity |
| WO2002000201A2 (en) | 2000-06-27 | 2002-01-03 | F. Hoffmann-La Roche Ag | Method for preparing a composition |
| AU2001289696B2 (en) * | 2000-07-28 | 2006-07-06 | Cheplapharm Arzneimittel Gmbh | New use of lipase inhibitors |
| ATE279961T1 (de) * | 2000-07-28 | 2004-11-15 | Hoffmann La Roche | Neue pharmazeutische zusammensetzung |
| JP4727901B2 (ja) | 2000-08-09 | 2011-07-20 | エフ．ホフマン−ラ ロシュ アーゲー | リパーゼ阻害物質の使用 |
| MXPA03003246A (es) | 2000-10-16 | 2003-06-06 | Hoffmann La Roche | Derivados de indolina y su uso como ligandos del receptor 5-ht2. |
| GB0030710D0 (en) | 2000-12-15 | 2001-01-31 | Hoffmann La Roche | Piperazine derivatives |
| ES2291374T3 (es) | 2000-12-27 | 2008-03-01 | F. Hoffmann-La Roche Ag | Derivados de indol y su empleo como ligandos receptores de 5-ht2b y 5-ht2c. |
| GB0106177D0 (en) | 2001-03-13 | 2001-05-02 | Hoffmann La Roche | Piperazine derivatives |
| ATE387428T1 (de) | 2001-05-21 | 2008-03-15 | Hoffmann La Roche | Chinolinderivate als liganden für den neuropeptid-y-rezeptor |
| US20030027786A1 (en) * | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| US6730319B2 (en) * | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
| US7049345B2 (en) * | 2001-06-29 | 2006-05-23 | Genzyme Corporation | Fat-binding polymers |
| US7041280B2 (en) * | 2001-06-29 | 2006-05-09 | Genzyme Corporation | Aryl boronate functionalized polymers for treating obesity |
| US6787558B2 (en) | 2001-09-28 | 2004-09-07 | Hoffmann-La Roche Inc. | Quinoline derivatives |
| GB0202015D0 (en) | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| KR100659428B1 (ko) | 2002-02-04 | 2006-12-19 | 에프. 호프만-라 로슈 아게 | Ｎｐｙ 길항제로서의 퀴놀린 유도체 |
| JP2005526732A (ja) | 2002-02-28 | 2005-09-08 | エフ．ホフマン−ラ ロシュ アーゲー | Ｎｐｙ受容体拮抗剤としてのチアゾール誘導体 |
| PL216022B1 (pl) * | 2002-04-26 | 2014-02-28 | Hoffmann La Roche | Kompozycja farmaceutyczna, sposób jej wytwarzania i jej zastosowanie, zestaw do leczenia otylosci, inhibitor lipazy w postaci orlistatu i glukomannan lub konjac, zastosowanie inhibitora lipazy w postaci orlistatu oraz zastosowanie glukomannanu lub konjacu |
| CN1665791A (zh) | 2002-07-05 | 2005-09-07 | 霍夫曼-拉罗奇有限公司 | 喹唑啉衍生物 |
| CA2493712A1 (en) | 2002-08-07 | 2004-02-19 | F. Hoffmann-La Roche Ag | Aminothiazole derivatives as npy5 receptor inhibitors |
| WO2004024726A1 (en) | 2002-09-12 | 2004-03-25 | F. Hoffmann-La Roche Ag | N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes |
| BR0316556A (pt) | 2002-11-25 | 2005-10-04 | Hoffmann La Roche | Compostos, processo para a preparação de um composto, composição farmacêutica que compreende esse composto, sua utilização e método para o tratamento e/ou profilaxia de enfermidades que são moduladas por agonistas ppar(alfa) e/ou ppary |
| US8372430B2 (en) | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
| GB0314967D0 (en) | 2003-06-26 | 2003-07-30 | Hoffmann La Roche | Piperazine derivatives |
| AU2004263312A1 (en) | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | Thiazole derivatives as NPY antagonists |
| AU2004263311A1 (en) | 2003-08-12 | 2005-02-17 | F. Hoffmann-La Roche Ag | 2-amino-5-benzoylthiazole NPY antagonists |
| CA2609634C (en) | 2005-05-03 | 2011-02-01 | F. Hoffmann-La Roche Ag | Tetracyclic azapyrazinoindolines as 5-ht2 ligands |
| WO2006132440A1 (ja) | 2005-06-09 | 2006-12-14 | Takeda Pharmaceutical Company Limited | 固形製剤 |
| ATE430744T1 (de) | 2005-08-18 | 2009-05-15 | Hoffmann La Roche | Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren |
| ATE507222T1 (de) | 2005-11-30 | 2011-05-15 | Hoffmann La Roche | 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren |
| KR101124156B1 (ko) | 2005-11-30 | 2012-03-23 | 에프. 호프만-라 로슈 아게 | 1,5-치환된 인돌-2-일 아마이드 유도체 |
| ATE466007T1 (de) | 2005-11-30 | 2010-05-15 | Hoffmann La Roche | 5-substituierte indol-2-carbonsäureamidderivate |
| US7579351B2 (en) | 2005-12-09 | 2009-08-25 | Hoffmann-La Roche Inc. | Tricyclic amide derivatives |
| KR20080068127A (ko) | 2005-12-15 | 2008-07-22 | 에프. 호프만-라 로슈 아게 | 피롤로[2,3-ｃ]피리딘 유도체 |
| KR101015666B1 (ko) | 2005-12-16 | 2011-02-22 | 에프. 호프만-라 로슈 아게 | Ｈ3 수용체 조절제로서 피롤로[2,3-ｂ]피리딘 유도체 |
| US7432255B2 (en) | 2006-05-16 | 2008-10-07 | Hoffmann-La Roche Inc. | 1H-indol-5-yl-piperazin-1-yl-methanone derivatives |
| WO2007137955A1 (en) | 2006-05-30 | 2007-12-06 | F. Hoffmann-La Roche Ag | Piperidinyl pyrimidine derivatives |
| US7514433B2 (en) | 2006-08-03 | 2009-04-07 | Hoffmann-La Roche Inc. | 1H-indole-6-yl-piperazin-1-yl-methanone derivatives |
| US20080146559A1 (en) | 2006-12-08 | 2008-06-19 | Li Chen | 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives |
| PT2147149T (pt) * | 2007-05-16 | 2017-05-03 | Buckman Laboratories Int Inc | Métodos para controlar contaminantes orgânicos em fibras |
| AU2008280257A1 (en) | 2007-07-25 | 2009-01-29 | F. Hoffmann-La Roche Ag | Benzofuran- and benzo[B]thiophene-2-carboxylic acid amide derivatives and use thereof as histamine 3 receptor modulators |
| WO2009044380A2 (en) | 2007-10-05 | 2009-04-09 | Ranbaxy Laboratories Limited | Formulations containing orlistat particles having controlled particle size |
| WO2009050720A1 (en) * | 2007-10-15 | 2009-04-23 | Inventis Dds Pvt Limited | Pharmaceutical composition of orlistat |
| PL216542B1 (pl) | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
| WO2010042499A1 (en) | 2008-10-06 | 2010-04-15 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
| GB201122213D0 (en) * | 2011-12-23 | 2012-02-01 | Norgine Bv | Compositions |
| CN104546768B (zh) * | 2014-12-30 | 2017-06-16 | 重庆植恩药业有限公司 | 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法 |
| BR112018075415A2 (pt) * | 2016-06-17 | 2019-03-12 | The Procter & Gamble Company | composição mastigável macia compreendendo plantago |
| CN112220831A (zh) * | 2020-08-07 | 2021-01-15 | 天津盛实百草中药科技有限公司 | 圆苞车前子壳粉在缓解奥利司他副作用中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4005195A (en) * | 1976-02-12 | 1977-01-25 | The Procter & Gamble Company | Compositions for treating hypercholesterolemia |
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| US5294451A (en) * | 1991-03-29 | 1994-03-15 | Curtice-Burns, Inc. | Fat substitute compositions having reduced laxative effects |
| CA2098167C (en) * | 1992-06-24 | 2006-12-19 | Dorothea Isler | Foodstuffs and feedstuffs containing a lipase inhibitor |
| TW381025B (en) * | 1993-08-05 | 2000-02-01 | Hoffmann La Roche | Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor |
| JPH09252746A (ja) * | 1996-03-22 | 1997-09-30 | Nippon Kankyo Yakuhin Kk | 栄養補助食品 |
| JP4202439B2 (ja) * | 1996-10-01 | 2008-12-24 | 江崎グリコ株式会社 | フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液 |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
-
1999
- 1999-08-02 TR TR2001/00471T patent/TR200100471T2/xx unknown
- 1999-08-02 KR KR1020017001801A patent/KR20010079635A/ko not_active Ceased
- 1999-08-02 DK DK99940127T patent/DK1105122T3/da active
- 1999-08-02 PT PT99940127T patent/PT1105122E/pt unknown
- 1999-08-02 EP EP99940127A patent/EP1105122B1/en not_active Expired - Lifetime
- 1999-08-02 WO PCT/EP1999/005607 patent/WO2000009122A1/en not_active Ceased
- 1999-08-02 BR BRPI9912980-9B1A patent/BR9912980B1/pt not_active IP Right Cessation
- 1999-08-02 CN CNB998095079A patent/CN1170534C/zh not_active Expired - Lifetime
- 1999-08-02 JP JP2000564625A patent/JP3774118B2/ja not_active Expired - Lifetime
- 1999-08-02 CA CA002340056A patent/CA2340056C/en not_active Expired - Lifetime
- 1999-08-02 AT AT99940127T patent/ATE293970T1/de active
- 1999-08-02 DE DE69924999T patent/DE69924999T2/de not_active Expired - Lifetime
- 1999-08-02 ES ES99940127T patent/ES2242413T3/es not_active Expired - Lifetime
- 1999-08-02 AU AU54185/99A patent/AU761351B2/en not_active Expired
- 1999-08-10 US US09/370,846 patent/US6358522B1/en not_active Expired - Lifetime
- 1999-08-10 CO CO99050689A patent/CO5130009A1/es unknown
- 1999-08-11 MA MA25725A patent/MA26671A1/fr unknown
- 1999-08-12 PE PE1999000820A patent/PE20000953A1/es not_active Application Discontinuation
- 1999-08-12 AR ARP990104054A patent/AR035001A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2340056C (en) | 2007-01-09 |
| KR20010079635A (ko) | 2001-08-22 |
| AU761351B2 (en) | 2003-06-05 |
| US6358522B1 (en) | 2002-03-19 |
| JP3774118B2 (ja) | 2006-05-10 |
| CN1170534C (zh) | 2004-10-13 |
| CO5130009A1 (es) | 2002-02-27 |
| JP2002522491A (ja) | 2002-07-23 |
| EP1105122A1 (en) | 2001-06-13 |
| MA26671A1 (fr) | 2004-12-20 |
| AR035001A1 (es) | 2004-04-14 |
| BR9912980A (pt) | 2001-05-08 |
| ATE293970T1 (de) | 2005-05-15 |
| TR200100471T2 (tr) | 2001-07-23 |
| WO2000009122A1 (en) | 2000-02-24 |
| DE69924999T2 (de) | 2006-05-04 |
| CN1312713A (zh) | 2001-09-12 |
| PT1105122E (pt) | 2005-08-31 |
| CA2340056A1 (en) | 2000-02-24 |
| DK1105122T3 (da) | 2005-08-08 |
| DE69924999D1 (de) | 2005-06-02 |
| EP1105122B1 (en) | 2005-04-27 |
| ES2242413T3 (es) | 2005-11-01 |
| AU5418599A (en) | 2000-03-06 |
| BR9912980B1 (pt) | 2013-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000953A1 (es) | Composiciones farmaceuticas que contienen un inhibidor de lipasas gastrointestinales | |
| Van Outryve et al. | “Prokinetic” treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride | |
| Elson et al. | Anti-carcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis | |
| Khaksar et al. | Effects of thyme essential oil on performance, some blood parameters and ileal microflora of Japanese quail | |
| AU719090B2 (en) | Oral preparation for the prophylactic and therapeutic treatment of helicobacter sp. infection | |
| Huff et al. | Effect of sea buckthorn berries and pulp in a liquid emulsion on gastric ulcer scores and gastric juice pH in horses | |
| BR9611802A (pt) | Composições farmacêuticas | |
| BR0309993A (pt) | Método para reduzir a produção de metano que emana das atividades digestivas de um animal, composição para alimentação, pré-mistura de alimentação, e, suplemento para água de beber | |
| TR200103566T2 (tr) | Alkalin sfingomiyelinazdan oluşan terkipin kullanılması | |
| IT1315252B1 (it) | Compresse gastroresistenti ad uso alimentare o dietetico ottenutemediante grassi miscelati alla massa | |
| PT1213972E (pt) | Composicao compreendendo um inibidor da alfa-amilase e pelo menos um composto fisiologicamente aceitavel capaz de reduzir a absorcao intestinal dos "acucares rapidos" | |
| MXPA05008403A (es) | Uso de acido comestible en formas de dosis solidas farmaceuticas de rapida dispersion. | |
| RU2006131758A (ru) | Композиция для предупреждения простуды | |
| WO2013067147A1 (en) | A composition and method of delivery of l-arabinose and select compounds | |
| Horwitz et al. | Lignans—additional benefits from fiber? | |
| RS62116B1 (sr) | Kompozicije koje sadrže geraniol i suvi đumbir za upotrebu u lečenju sindroma iritabilnog kolona | |
| RU2010125503A (ru) | СОДЕРЖАЩАЯ КОМБИНАЦИЮ ЦЕОЛИТ/ВОДОРОСЛИ ИЛИ ЦЕОЛИТ/ЭМУЛЬСИЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ЛЕЧЕНИЯ СПИДа | |
| CN104173940B (zh) | 药物组合物及其应用、保健食品、药物制剂 | |
| TH75658A (th) | ผลิตภัณฑ์รักษาโรคคลองรากฟัน | |
| RU2005141423A (ru) | Пищевые композиции и способ ингибирования ими сокращения гладкомышечной клетки | |
| AR066667A1 (es) | Composiciones farmaceuticas que comrenden la combinacion de un agente derivado hidrogenado de lipstatina y un agente inhibidor de hmg coa reductasa | |
| RU2000128721A (ru) | Композиция для новообразования коллагена | |
| Nagib | Effect of Basil (Ocimum basilicum L.) and Its oil on postmenopausal female rats | |
| ES2179789B1 (es) | Una composicion para la perdida de peso y el control de la obesidad. | |
| Gong et al. | How effective is bupropion augmentation for SSRI-induced sexual dysfunction? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |